MedTrace Logo

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

NCT04806373 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-06-08

Study results available
· View outcomes & findings →

Summary

Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion.

Conditions

  • Pleural Effusion

Interventions

DRUG

Cathflo Activase

Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter

DRUG

Talc Slurry Pleurodesis

Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Memorial Healthcare System

    lead OTHER

Principal Investigators

  • Mark Block, MD · Chief, Thoracic Surgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2023-12-14
Completion
2023-12-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04806373 on ClinicalTrials.gov